Complex Civil Litigation Law Firm

If you suffered significant losses in Aquestive Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST). STOCK DROP: Shares of Aquestive Therapeutics, Inc. (NASDAQ: AQST) plunged approximately 40% intraday on Friday after the company disclosed that the U.S. Food and Drug Administration (FDA) identified deficiencies in its New Drug Application (NDA) for Anaphylm, its experimental sublingual film for the treatment of severe allergic reactions, including anaphylaxis. The FDA advised that the unidentified deficiencies currently prevent discussions of labeling and post-marketing requirements, raising concerns about the application’s approvability ahead of the January 31, 2026, PDUFA action date.

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ardent Health, Inc. (“Ardent” or the “Company”) (NYSE: ARDT) and reminds investors of the March 9, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose information regarding Ardent Health’s accounts receivable. During the Class Period, Defendants publicly reported the Company’s accounts receivable on a quarterly basis. In addition, Defendants represented that the Company maintained professional malpractice liability insurance in amounts “sufficient to cover claims arising out of its operations.” Lead Plaintiff Deadline: March 9, 2026  Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) Or submit your information below to learn about your rights.

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Varonis Systems, Inc. (“Varonis” or the “Company”) (NASDAQ: VRNS) and reminds investors of the March 9, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: Defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Varonis’ ability to convert its existing customer base; notably, that it was not truly equipped to convince existing users of the benefits of converting to the SaaS offering or otherwise maintain those customers on its platform, resulting in significantly reduced ARR growth potential in the near-term. Such statements absent these material facts caused Plaintiff and other shareholders to purchase Varonis’ securities at artificially inflated prices. Lead Plaintiff Deadline: March 9, 2026  Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) Or submit your information below to learn about your rights.

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Fermi Inc. (“Fermi” or the “Company”) (NASDAQ: FRMI) and reminds investors of the March 6, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the Company overstated its tenant demand for its Project Matador campus; (2) the extent to which Project Matador would rely on a single tenant’s funding commitment to finance the construction of Project Matador; (3) there was a significant risk that that tenant would terminate its funding commitment; and (4) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. Lead Plaintiff Deadline: March 6, 2026  Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) Or submit your information below to learn about your rights.